Affymetrix Revenues Rise for 2001, As Comeback Company Reports Solid Q4 | GenomeWeb

NEW YORK, Jan. 30 - For Affymetrix, 2001 could have been an annus horribilis. The company began the year with the revelation that its murine chips were defective, a whopping $19 million-plus settlement payment to end litigation with Oxford Gene Technology, and a pack of competitors nipping at its heels.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.